Abstracts tagged "immunology"

Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: 2463 • ACR Convergence 2025
Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
Chunnei Yang¹, Chuanyin Sun², Binghe Tan³, Chao Hu¹, Liyan Wan², Changling Xie³, Qian Tan³, Mingyao Liu³, Jin Lin², Bing Du³ and Hongyan Tong¹, ¹Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), ²Department of Rheumatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), ³BRL Medicine Inc., Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with significant morbidity and mortality. The treatment approach for SLE primarily involves immunomodulation and…
Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Carmen Secada-Gómez¹, Ligia Gabrie-Rodriguez², Hector Ulloa-Alvarado³, Giuliano Boselli⁴, Camilo Veloza-Morales⁵, Diana Prieto-Peña⁶, juan Irure-Ventura⁷, Marcos López-Hoyos⁸ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁴Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁵Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…
Abstract Number: 1724 • ACR Convergence 2025
Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.
Manon LESTURGIE-TALAREK¹, Virginie Gonzalez², Anne Cauvet², Lucie Beaudoin³, Fiona Oudart⁴, Adrien Schvartz⁵, Francesco Carbone⁵, Mickael Menager⁵, Noémie Sénot³, Francoise Tilotta⁶, Yannick Allanore⁷, Agnes Lehuen⁸ and Jérôme AVOUAC⁹, ¹Paris University, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Institut Cochin, Paris, ⁴APHP - Cochin hospital, Paris, France, ⁵Institut Imagine, Paris, ⁶Université Paris Cité, Montrouge, France, ⁷Université Paris Cité, Paris, France, ⁸Hôpital Cochin, Paris, France, ⁹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that produce cytokines and cytotoxic molecules. Reduced frequencies and altered phenotypes of MAIT cells have been…
Abstract Number: 1155 • ACR Convergence 2025
Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
Nada Elbuluk¹, Melinda J. Gooderham², Jessamyn Blau³, Wenwen Zhang³, Ejim Mark³, Warren Winkelman³ and Mark Lebwohl⁴, ¹Department of Dermatology, USC Keck School of Medicine, Los Angeles, CA, ²SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ³Takeda Development Center Americas, Inc., Cambridge, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Zasocitinib (TAK-279) is an investigational, highly selective and potent, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial of moderate-to-severe plaque…
Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Christopher Moore¹, Travis Drow², Peter Cook², Annaiz Grimm², Victoria DeVault-Nelson¹, Jennifer Mellen¹, Payam Zarin¹, Alaina Burgess¹, Maegan Hoover¹, Tingxi Guo¹, Brock McKinney², Noelle Dahl², Aesha Vakil², Brian Christin³, Gene Uenishi¹, Tiffany Chen¹, Alberto Del Rio-Espinola⁴, David Rawlings² and Tom Wickham¹, ¹GentiBio, Cambridge, ²SCRI, Seattle, ³GentiBio, Seattle, ⁴GentiBio, Basel, Switzerland
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
Abstract Number: 0555 • ACR Convergence 2025
Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
Melinda J. Gooderham¹, Edward Lain², Robert Bissonnette³, Yu-Huei Huang⁴, Charles Lynde⁵, Matthias Hoffmann⁶, Joseph F Merola⁷, Eingun J. Song⁸, Jessica H. Rubens⁹, Amy M. DeLozier⁹, Ming-Chun Hsu⁹ and Richard B. Warren¹⁰, ¹SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ²Austin Institute for Clinical Research, Sanova Dermatology, Austin, TX, USA, Austin, TX, ³Innovaderm Research, Montreal, QC, Canada, Montreal, QC, ⁴Chang Gung Memorial Hospital & Chang Gung University, Taoyuan City, Taiwan, Taoyuan City, Taiwan (Republic of China), ⁵University of Toronto, Lynde Institute for Dermatology & Lynderm Research Inc, Markham, ON, Canada, ON, Canada, ⁶Dermatology Practice Dr. M Hoffmann, Witten, Germany, Witten, Germany, ⁷Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁸Frontier Derm, Mill Creek, WA, USA, WA, ⁹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁰Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Icotrokinra (ICO), a first-in-class, targeted oral peptide that binds and inhibits the interleukin (IL)-23R, was evaluated in ICONIC-TOTAL (NCT06095102).Methods: This Phase 3 trial included…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 2461 • ACR Convergence 2025
Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
Alexandra Ainatzoglou¹, Georgia-Savina Moysidou², Danae-Mona Nöthling³, Fanouriakis Antonis⁴, George Bertsias⁵, Panagiotis Garantziotis³, Georg Schett⁶ and Dimitrios Boumpas⁷, ¹⁴th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Athens, Greece, ²Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Athens, Greece, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁵Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ⁶Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁷Joint Rheumatology Program, University of Athens Medical School, Athens, Greece
Background/Purpose: Systemic lupus erythematosus (SLE) therapies elicit distinct transcriptional responses, yet a subset of patients fails to achieve clinical remission. To guide precision repurposing, we…
Abstract Number: 2020 • ACR Convergence 2025
Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial
Arezou Khosroshahi¹, Emma Culver², Wen Zhang³, Kazuichi Okazaki⁴, Yoshiya Tanaka⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone⁹, ¹Emory University, Atlanta, GA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁴Kansai Medical University Kori Hospital, Osaka, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 1723 • ACR Convergence 2025
Impaired Maintenance of X-Chromosome Inactivation in B Cells, But Not T Cells, Exacerbates Interferon-Driven Systemic Autoimmunity
Nikhil Jiwrajka¹, Claudia Lovell¹, Zowie Searcy¹, Katherine Forsyth¹, Emma Welter¹, Natalie Toothacre², Nuriban Valero-Pacheco¹, Katherine Premo¹ and Montserrat Anguera¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia
Background/Purpose: Many systemic autoimmune diseases associated with chronic type 1 interferon (IFN) signaling, including SLE, SjD, and SSc, preferentially afflict females. The biological basis of…
Abstract Number: 1141 • ACR Convergence 2025
Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages
Sadiq Umar¹, Kasey Leung² and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago, IL
Background/Purpose: Gout is the most prevalent form of inflammatory arthritis, with rising global incidence. It results from the deposition of monosodium urate (MSU) crystals in…
Abstract Number: 0979 • ACR Convergence 2025
IL-23 upregulates IFN-γ secretion in Th17.1, but not in Th17 or classical Th1 cells
Bennie van Heeswijk¹, Wida Razawy², Anne-Marie Mus-Otten³, Patrick Asmawidjaja², Pieter Leenen² and Erik Lubberts⁴, ¹Erasmus MC, University Medical Center Rotterdam, Hoofddorp, Netherlands, ²Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ³Erasmus medical center, Rotterdam, Netherlands, ⁴Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Interleukin-23 (IL-23) is a key cytokine in the pathogenesis of psoriatic diseases, as demonstrated by the clinical success of IL-23-targeted therapies. Monocytes are a…
Abstract Number: 0890 • ACR Convergence 2025
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
Julia Nicole Zeid¹, Kaitlyn Arce², Nanxi Guo¹, Kartik Bhamidipati³, Kevin Wei⁴, Larry Moreland⁵, Fan Zhang⁶ and Anna Helena Jonsson², ¹University of Colorado School of Medicine, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵University of Colorado, Denver, CO, ⁶The University of Colorado, Aurora, CO
Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…

1
2
3
…
33
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].